Pediatrics

Updated Consensus Definition

Contemporary BPD definitions (2018 NICHD workshop and updates) grade severity based on respiratory support required at 36 weeks postmenstrual age (infants born <32 weeks) rather than a simpler oxygen requirement at 28 days — better reflecting pathophysiology and correlating with long-term pulmonary outcome. Grading incorporates no support, low-flow oxygen, non-invasive support (CPAP/NIPPV/high-flow), or invasive ventilation at 36 weeks.

Pathogenesis — “Old” versus “New” BPD

“Old” BPD (pre-surfactant/antenatal steroid era) occurred in relatively more mature preterm infants exposed to aggressive mechanical ventilation and high oxygen, producing severe airway epithelial injury, smooth muscle hypertrophy, and extensive parenchymal fibrosis.

“New” BPD, the dominant modern pattern, affects extremely preterm, ELBW survivors whose lungs are arrested at an early developmental stage. The defining feature is disrupted alveolar and pulmonary microvascular development — fewer, larger, simplified alveoli with a dysmorphic, reduced microvasculature, rather than severe fibrosis — reflecting extreme prematurity itself plus chorioamnionitis, sepsis, hemodynamically significant PDA, oxidative stress, and milder ventilator-associated injury.

Strategies for Lung-Protective Ventilation

• Prioritizing non-invasive support (CPAP, NIPPV) from the delivery room onward
• Volume-targeted ventilation modes when invasive ventilation is necessary
• Permissive hypercapnia to allow lower tidal volumes/pressures
• Minimizing total duration of invasive ventilation with proactive extubation
• Caffeine citrate — reduces apnea, facilitates extubation, and (CAP trial) reduces BPD incidence and improves neurodevelopmental outcome
• Judicious, individualized oxygen therapy avoiding both hypoxemia and hyperoxia

Postnatal Steroids

Systemic dexamethasone facilitates extubation and reduces BPD incidence, but early high-dose use is associated with increased cerebral palsy risk. Current practice reserves systemic dexamethasone for very high-risk infants, using the lowest effective cumulative dose, initiated later (typically after 1–2 weeks) with explicit informed discussion. Hydrocortisone is a potentially safer alternative in select populations (PREMILOC trial), though evidence and optimal patient selection remain areas of ongoing study.

Long-Term Management

Increased caloric/nutritional demands, diuretic therapy for fluid management, bronchodilator therapy where indicated, RSV prophylaxis (palivizumab) in eligible high-risk infants, and structured long-term pulmonary and neurodevelopmental follow-up.

Pathophysiology

Meconium-stained amniotic fluid results from intrauterine fetal distress/hypoxia (vagally-mediated peristalsis and sphincter relaxation) or physiological post-term passage. Aspiration produces lung injury via several mechanisms:

• Mechanical airway obstruction — ball-valve effect producing regional hyperinflation, air trapping, and air leak risk
• Chemical pneumonitis — bile acids, pancreatic enzymes provoke intense inflammation independent of infection
• Surfactant inactivation — secondary, acquired deficiency producing a patchy, heterogeneous pattern (hyperinflation adjacent to atelectasis), distinct from RDS
• Frequent association with PPHN — the same chronic intrauterine hypoxic stress causing meconium passage often causes abnormal pulmonary vascular remodeling (“maldevelopment” pathway)

Clinical Presentation

Typically a term or post-term infant with meconium staining of skin, nails, and cord. Respiratory distress from birth or shortly after: tachypnea, grunting, nasal flaring, retractions, cyanosis. Chest may appear barrel-shaped/hyperinflated.

Radiological Findings

Patchy, coarse, asymmetric infiltrates alternating with hyperinflation/air trapping (heterogeneous “ropey” appearance), flattened hemidiaphragms, and possible air leak (pneumothorax, pneumomediastinum).

Current Management Recommendations

• Routine intrapartum oro/nasopharyngeal suctioning on the perineum before shoulder delivery is NO LONGER recommended
• Routine elective tracheal intubation/suctioning is NOT recommended for a vigorous infant, even with meconium-stained fluid
• For a non-vigorous infant — standard initial resuscitation steps begin; tracheal suctioning under direct laryngoscopy may be considered if airway obstruction impedes ventilation, but must not delay PPV

Ongoing management: respiratory support titrated to severity (often HFOV in severe cases), surfactant replacement (also has a possible lavage benefit), management of associated PPHN following the standard therapeutic ladder, empirical antibiotics (given difficulty distinguishing MAS from congenital pneumonia), and close monitoring for air leak complications.

Differential Diagnosis of Neonatal Respiratory Distress

TTN, RDS, Meconium Aspiration Syndrome, congenital pneumonia/sepsis (particularly early-onset GBS), pneumothorax, structural/congenital anomalies (CDH, congenital pulmonary airway malformation, tracheoesophageal fistula ± esophageal atresia), PPHN, congenital heart disease (particularly cyanotic lesions), and polycythemia/hyperviscosity syndrome.

Pathogenesis of TTN

In utero, fetal lungs are fluid-filled. Clearance occurs via (1) mechanical thoracic compression during vaginal delivery, and (2) active transepithelial reabsorption via epithelial sodium channels (ENaC), upregulated by the catecholamine surge of labor. TTN results from delayed clearance, more common after elective Cesarean without labor (no vaginal squeeze, no full catecholamine surge). Additional risk factors: late-preterm birth, maternal diabetes, macrosomia, male sex.

Clinical Features

Onset within the first few hours of life: prominent tachypnea (RR often >60/min), mild-moderate distress (grunting, flaring, mild retractions), mild-moderate oxygen requirement. Distinguishing feature: self-limiting course, resolving within 24–72 hours, without RDS's progressive worsening pattern.

Radiological Findings

Prominent perihilar streaking, fluid within interlobar fissures, mild hyperinflation, occasionally small pleural effusions — distinguishable from RDS's diffuse reticulogranular, low-volume appearance.

Management

Primarily supportive: supplemental oxygen as needed, close monitoring for resolution over 24–72 hours. Enteral feeding often withheld/cautious given aspiration risk during rapid breathing. Empirical antibiotics are frequently initiated pending cultures given difficulty distinguishing TTN from early sepsis/pneumonia, discontinued once cultures return negative.

Operational Definitions

Contemporary practice uses an “operational threshold” rather than a single fixed value, since risk of harm varies with postnatal age, symptoms, and risk factors. General practice targets blood glucose <45–50 mg/dL as warranting intervention in at-risk infants during the first 24 hours, with progressively higher thresholds expected as age increases. Hypoglycemia persistent/recurrent beyond 48–72 hours, or requiring a glucose infusion rate >10–12 mg/kg/min, is abnormal and mandates specific endocrine/metabolic evaluation.

Diagnostic Approach — The “Critical Sample”

The single most diagnostically valuable step is a blood (and urine, where feasible) sample collected at the actual moment of hypoglycemia, before correction. Panel: glucose, insulin, cortisol, growth hormone, beta-hydroxybutyrate (ketones), free fatty acids, lactate, ammonia, and acylcarnitine profile (± urine organic acids).

Interpretation Pattern

Evaluation for Congenital Hyperinsulinism

• Genetic testing: ABCC8 and KCNJ11 mutations (KATP channel subunits) are the most common identifiable causes and determine pharmacotherapy responsiveness; rarer causes include GLUD1 (hyperinsulinism-hyperammonemia syndrome) and activating GCK mutations
• ¹⁸F-DOPA PET-CT scanning — distinguishes focal disease (amenable to curative focal resection) from diffuse disease (medical management or near-total pancreatectomy)
• Diazoxide is first-line, opening KATP channels to suppress insulin secretion; infants with complete channel loss-of-function are characteristically diazoxide-unresponsive
• Octreotide used for diazoxide-unresponsive cases pending definitive management
• Surgical management (focal resection or near-total pancreatectomy) reserved for medically refractory cases

Antenatal Diagnosis

Typically identified on routine antenatal ultrasound: abdominal viscera within the thoracic cavity, mediastinal shift, and often polyhydramnios. Severity assessment uses the lung-to-head ratio (LHR) and observed-to-expected LHR (o/e LHR), plus fetal MRI percentage predicted lung volume. Liver herniation into the thorax is an important independent adverse prognostic marker.

Stabilization in the Delivery Room

• Immediate endotracheal intubation is essential — bag-mask ventilation must be avoided (risks insufflating the herniated stomach/bowel, worsening lung compression)
• Immediate orogastric/nasogastric tube placement with continuous suction to decompress herniated gas-filled bowel
• Gentle ventilation instituted from the first breaths

Gentle Ventilation Strategy (“Permissive Hypercapnia”)

• Permissive hypercapnia — tolerating elevated PaCO₂ in exchange for lower peak pressures/tidal volumes
• “Gentle” conventional ventilation initially, escalating to HFOV if inadequate
• Deliberate hyperventilation-induced alkalosis is no longer recommended, superseded by permissive hypercapnia

Pulmonary Hypertension Management

CDH is near-universally associated with PPHN (the “underdevelopment” category) — managed with standard PPHN principles (careful oxygenation, echocardiographic monitoring, iNO first-line, sildenafil/milrinone adjuncts, ECMO for refractory cases). CDH-associated PPHN is a classic indication for neonatal ECMO.

Timing of Surgical Repair

CDH repair is explicitly NO LONGER a surgical emergency. Delayed repair follows physiological stabilization — surgery deferred until stable oxygenation/hemodynamics with pulmonary hypertension reasonably controlled (may take days to weeks). This reflects evidence that subjecting an unstable infant to emergency surgery worsens outcomes. Repair may be open (laparotomy/thoracotomy) or minimally invasive thoracoscopic in stable infants. ECMO may serve as a pre-operative bridge or, less commonly, for post-operative deterioration.

Evidence-Based Benefits of KMC

A substantial evidence base, including the landmark WHO-led iKMC (immediate Kangaroo Mother Care) trial, demonstrates KMC significantly reduces neonatal mortality in eligible low birth weight/preterm infants — including benefit when initiated early and continuously in initially unstable infants (even those requiring respiratory support or IV fluids). Additional benefits: reduced hypothermia, reduced nosocomial infection/sepsis, reduced severe illness episodes, improved weight gain, higher exclusive breastfeeding rates, improved bonding/maternal wellbeing, and evidence of improved long-term neurodevelopmental outcomes.

Eligibility Criteria

Traditional practice restricted KMC to clinically stable infants. Updated WHO iKMC guidance now supports early, continuous KMC even in initially unstable infants, including those on respiratory support or IV fluids — initiation recommended as soon as possible after birth rather than delaying until an arbitrary stability threshold.

Components of KMC

1. Skin-to-skin contact — infant (diaper/nappy and cap only) positioned prone and upright against the bare chest of the mother or another caregiver, secured with a wrap, for as many hours daily as feasible — provides thermoregulation, physiological stabilization, and bonding
2. Exclusive or predominant breastfeeding, actively facilitated by KMC positioning
3. Support structures — practical support for mother/family and health-system support (staff training, ward design, continuation after discharge)

Impact on Mortality in VLBW Infants

The mortality benefit is most pronounced in VLBW infants (<1500g), reflecting the particular value of thermoregulation, cardiorespiratory stability, and infection risk reduction in the most vulnerable population — a low-cost, high-impact intervention, notably a cornerstone of India's national newborn care strategy.

Congenital Cytomegalovirus (CMV)

The most common congenital infection overall; the great majority of infected infants are asymptomatic at birth.

Symptomatic congenital CMV (~10% of infected infants): microcephaly, periventricular calcifications, sensorineural hearing loss (the most common and important long-term sequela, often progressive/delayed onset), chorioretinitis, hepatosplenomegaly, direct hyperbilirubinemia, petechiae/purpura (“blueberry muffin” rash), and thrombocytopenia.

Asymptomatic congenital CMV (~90%): appear well at birth, but ~10–15% subsequently develop sensorineural hearing loss — underscoring the need for audiological surveillance even in apparently healthy infants.

Laboratory evaluation: urine or saliva CMV PCR must be performed within the first 21 days of life to reliably confirm congenital (vs. postnatally/perinatally acquired) infection.

Treatment: oral Valganciclovir for symptomatic congenital CMV, particularly with CNS involvement, given for a 6-month course — improves audiological and neurodevelopmental outcomes vs shorter courses. Neutropenia is a common, expected adverse effect requiring monitoring.

Congenital Toxoplasmosis

Classic triad: chorioretinitis, hydrocephalus (typically aqueductal obstruction/inflammation), and intracranial calcifications — characteristically diffuse and scattered, in contrast to CMV's periventricular distribution.

Laboratory evaluation: maternal serology combined with infant IgM/IgA (which, unlike IgG, do not cross the placenta and indicate the infant's own immune response). Amniotic fluid PCR allows antenatal diagnosis; infant blood/CSF PCR supports postnatal diagnosis. Ophthalmological exam and neuroimaging complete the workup.

Treatment: pyrimethamine, sulfadiazine, and folinic acid (leucovorin) for a prolonged course (typically 12 months). Folinic acid co-administration is essential (not optional) — pyrimethamine is a folate antagonist and, without folinic acid, causes bone marrow suppression; the parasite cannot use exogenous folinic acid, so remains susceptible while host cells are “rescued.”

Hemodynamically Significant PDA (hsPDA) — The Central Concept

Not every anatomically patent ductus requires treatment — the distinction between anatomical patency and true hemodynamic significance is central. A hemodynamically significant PDA produces two parallel adverse consequences via left-to-right shunting: pulmonary overcirculation (edema risk, worsening respiratory status, prolonged ventilator dependence) and systemic hypoperfusion/“diastolic steal” (blood diverted through the ductus during diastole, affecting the gut — implicated in NEC risk — and brain — implicated in IVH risk).

Echocardiographic Parameters for hsPDA

• Ductal diameter — larger diameter generally correlates with greater shunt volume
• Left Atrium-to-Aortic root ratio (LA:Ao) — elevated ratio (commonly >1.4–1.5) reflects left-sided volume overload
• Left ventricular output and LV end-diastolic dimension — typically increased
• Diastolic flow reversal in the descending aorta, celiac artery, or MCA — marker of the “steal” phenomenon
• Pattern of ductal flow on Doppler (growing, pulsatile, or restrictive)

Medical Management

Indications for Closure — An Evolving, Increasingly Conservative Approach

Management has shifted substantially, driven by trial evidence that many PDAs close spontaneously and that routine, universal treatment based on anatomical patency/murmur alone does not improve (and may worsen) outcomes. Contemporary practice favors a targeted, individualized strategy — treatment reserved for infants with clear echocardiographic hemodynamic significance combined with clinical consequences (respiratory deterioration, ventilator-weaning difficulty, feeding intolerance).

Surgical or transcatheter closure: reserved for failure of adequate pharmacological treatment (typically 1–2 courses) or clear contraindication. Transcatheter device closure is increasingly performed even in quite small preterm infants at specialized centers, offering a less invasive alternative to surgical ligation (which carries a recognized association with subsequent vocal cord paralysis/BPD).

Classification of Neonatal Seizures

Clinical patterns include subtle seizures (oral-buccal-lingual movements, ocular phenomena, autonomic changes — the most frequently observed but least specific pattern), clonic seizures (rhythmic jerking, focal or multifocal), tonic seizures (sustained posturing), and myoclonic seizures (brief, shock-like jerks).

Electroclinical Dissociation

A defining, frequently-tested characteristic: clinical manifestations correlate poorly with underlying EEG seizure activity. Many encephalopathic, sedated, or paralyzed neonates experience purely electrographic seizures with no visible clinical correlate, while conversely, some observed motor behaviors correspond to no electrographic activity. This reflects the relative immaturity of cortical-subcortical connections and is the key reason EEG monitoring, not clinical observation alone, is essential for diagnosis and treatment-response assessment.

Underlying Aetiologies

HIE is the single most common cause overall. Others include intracranial hemorrhage (IVH, subdural hemorrhage), CNS infection (bacterial meningitis, viral encephalitis including HSV), metabolic derangements (hypoglycemia, hypocalcemia, hypomagnesemia, hyponatremia), inborn errors of metabolism, cerebral infarction/perinatal stroke, structural brain malformations, and specific genetic/epileptic encephalopathy syndromes — with pyridoxine-dependent epilepsy deserving particular mention as a rare, dramatically treatable cause in refractory seizures.

EEG Monitoring Modalities

• aEEG — simplified, continuous, bedside-compatible; reduced sensitivity vs full EEG, but useful for background pattern prognostication (particularly in HIE)
• Continuous conventional video-EEG — gold standard, most sensitive/specific, allows direct clinical-electrographic correlation; particularly recommended for infants undergoing therapeutic hypothermia

First and Second-Line Anticonvulsant Protocols

• First-line: Phenobarbital — achieves control as monotherapy in only ~40–50% of cases, with longstanding concerns regarding prolonged exposure effects on the developing brain
• Second-line: Levetiracetam — increasingly favored given a more favorable safety/tolerability profile (minimal hemodynamic/respiratory depression, no routine level monitoring); Fosphenytoin/phenytoin — alternative, complicated by a narrow therapeutic window and complex pharmacokinetics
• Refractory seizures: midazolam continuous infusion; consider a specific pyridoxine (Vitamin B6) trial in refractory seizures without a clear cause

Throughout, treatment of the underlying identified cause proceeds in parallel with anticonvulsant therapy.

Pathophysiological Basis — Compensatory Blood Flow Redistribution

During significant hypoxic-ischemic insult, the circulation mounts a “diving reflex”-like redistribution, preferentially maintaining flow to the brain, heart, and adrenal glands at the expense of kidneys, GI tract, liver, and peripheral tissues. This explains why multi-organ dysfunction in the “sacrificed” organs is often evident early, while the brain may initially appear relatively spared — until, with sufficiently severe/prolonged asphyxia, even the preferentially-perfused organs sustain injury, manifesting as HIE.

Multi-Organ Systemic Impacts — A Systems-Based Review

Diagnostic Workup and Supportive Care

Comprehensive, systematic multi-system monitoring: serial renal function/urine output, cardiac assessment (echo, troponin trending), hepatic function/coagulation profile, blood glucose, electrolytes (sodium/SIADH surveillance, calcium), and blood gas/lactate trending.

Supportive management is systems-targeted: careful individualized fluid management (balancing SIADH/cerebral edema risk against AKI-related renal perfusion needs), inotropic support for cardiac dysfunction, aggressive glucose/calcium correction, coagulopathy correction, and — of overriding importance — therapeutic hypothermia (see Q2) for any infant meeting HIE eligibility criteria, since neurological outcome remains the dominant determinant of long-term morbidity.